MedGadget blog tells us about a new dry powder inhaler that, according to Cambridge Consultants and India's Sun Pharma Advanced Research Company (SPARC), delivers an even drug dose deep into the lungs no matter how strong the patient's inhalation.
The device uses a "de-agglomeration engine" to separate the drug from the lactose 'carrier' particles. The companies say, based on a highly efficient airway design, the drug separation mechanism has successfully completed clinical trials and demonstrated that it is capable of delivering significantly more of the drug to the deep lung than traditional inhalers. This will reduce side-effects from drug build-up in the back of the throat and will mean that about half of the active drug needs to be loaded into the device compared with a standard inhaler.
The change in inhaler technology is a reliable and easy to use device, particularly for patients with impaired lung function or those using the inhaler during an asthma attack--overcoming any patient concerns about the ability to use the device effectively, the companies say.
- see the Cambridge release
- read the MedGadget report